変化する喘息のエンドタイプ:生物学的治療の進歩のために1型および2型炎症を統合する
Picheswara Rao Polu1, Vamsi Krishna Bikki2
1Research and Development Cell, Department of Intellectual Property Rights, Lovely Professional University, Phagwara, Punjab, India.
まとめ
タイプ1 (T1) とタイプ2 (T2) の喘息の内型を理解することは,精密治療の鍵です. T1/T2の洞察を統合することで,複雑な喘息の症例における生物学的治療選択と患者のアウトカムが改善されます.
科学分野:
- 肺医学
- 免疫学
- 薬理学について
背景:
- 喘息は,異なる炎症経路に基づいて1型 (T1) と2型 (T2) のエンドタイプに分類される.
- T2炎症は,既定のバイオマーカーと標的生物学的物質を含むIL-4,IL-5,IL-13を含む.
- T1炎症にはIFN-γ,TNF-α,IL-17,中性粒子が含まれており,有効なバイオマーカーと効果的な治療法がない.
研究 の 目的:
- T1 と T2 喘息のエンドタイプに関する現在の知識を統合する.
- T1とT2の内型を理解することで,精密な生物学的治療法の選択を進める方法を評価する.
- 患者さんの喘息治療の成果を向上させるため
主な方法:
- PubMed,Embase,Cochraneのデータベースからピアレビューされた論文の包括的な文献レビュー.
- 臨床試験のレジストリ,規制文書,会議の議事録を含む.
- T1/ T2経路,バイオマーカー,治療効果,エンドタイプによる戦略の関連性に基づく試験選択.
主要な成果:
- T2喘息は,有効なバイオマーカー (FeNO,血中エオシノフィールなど) と有効な生物学的薬 (抗IL-5,抗IL-4Rαなど) を有している.
- T1型喘息には 有効なバイオマーカーや治療法がありません
- 新興の証拠は,重度の喘息でT1/T2の重複を示し,二分型分類に挑戦しています.複数の経路をターゲットにすることが有望です.
結論:
- 検証されたバイオマーカーとマルチオミクスを通じてT1とT2の内型特性を統合することは,喘息の精密医療において極めて重要です.
- 将来の治療法は,最適な生物学的治療法の選択のために,内型可塑性および混合炎症に対処する必要があります.
- 先進的なエンドタイプ指針による戦略により,異質な喘息集団における治療結果の改善が期待される.
関連する概念動画
01:26Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
01:20Asthma: Pathogenesis and Management
576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
451
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
451
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:29Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
461
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
461